Objective To observe the clinical efficacy of paclitaxel plus neoadjuvant chemotherapy with loba-platin in patients with locally advanced cervical cancer, and to analyze its impact on serum decoy receptor 3 (DcR3) and apoptosis-suppressing gene Survivin level. Methods Seventy-eight patients of locally advanced cervical cancer under-going hysterectomy in Department of Obstetrics and Gynecology in our hospital from August 1st, 2014 to August 1st, 2015 were chosen and randomly divided into the observation group and the control group according to random number table, with 39 patients in each group. The control group was treated with routine total hysterectomy directly, and the ob-servation group was treated with paclitaxel plus neoadjuvant chemotherapy with lobaplatin for two courses (four consec-utive weeks) before total hysterectomy. Pathological indexes were detected in patients before surgery, and DcR3 and Sur-vivin levels in the two groups of patients were detected 1 month after surgery. The clinical efficacy, and incidence of gastro-intestinal adverse reactions, bone marrow suppression were compared between the two groups. Results Before treatment, serum DcR3 and Survivin levels had no statistically significant difference between the two groups (P>0.05). After treat-ment, serum DcR3 and Survivin levels in the observation group were significantly lower than those in the control group ((69.75±11.87) pg/ml vs (79.52±14.35) pg/mL, (76.26±14.26) ng/mL vs (87.32±15.17) ng/mL, P<0.05). The total effective rate of the observation group was 82.05%(32/39), which was slightly higher than 71.79%(28/39) in the control group, with no statistically significant difference (P>0.05). The incidence of gradeⅠgastrointestinal reactions and gradeⅠbone marrow suppression was higher in the observation group than the control group (51.28% (20/39) vs 30.77%, 15.38% (6/39) vs 2.56%, P<0.05). Conclusion Two to three cycles of paclitaxel plus neoadjuvant chemotherapy with lobaplatin before oper-ation in patients with locally advanced cervical cancer will help to reduce serum levels of DcR3 and Survivin, and improve the clinical effect.%目的：观察紫杉醇联合洛铂新辅助化疗治疗局部晚期宫颈癌的疗效，探讨其对患者血清诱捕受体3(DcR3)及凋亡抑制基因(Survivin)水平的影响。方法选择2014年8月1日至2015年8月1日我院妇产科行子宫切除手术的局部晚期宫颈癌患者78例，按照随机数表法将其分为观察组和对照组各39例。对照组患者直接进行常规的子宫全切除手术治疗，观察组患者术前先进行两个疗程(连续四周)的紫杉醇联合洛铂新辅助化疗，再进行子宫全切除手术。术前检测两组患者的病理情况，术后1个月检测两组患者体内血清中DcR3和Survivin水平，比较两组患者的临床疗效以及消化道、骨髓抑制等不良反应情况。结果治疗前，两组患者血清DcR3和Survivin水平比较差异均无统计学意义(P>0.05)，治疗后，观察组患者的DcR3和Survivin水平分别为(69.75±11.87) pg/mL和(76.26±14.26) ng/mL，均明显低于对照组的(79.52±14.35) pg/mL和(87.32±15.17) ng/mL，差异均有统计学意义(P<0.05)；观察组患者的总有效率为82.05%(32/39)，高于对照组的71.79%(28/39)，但差异无统计学意义(P>0.05)；观察组患者的消化道反应Ⅰ级和骨髓抑制Ⅰ级发生率分别为51.28%(20/39)和15.38%(6/39)，均高于对照组的30.77%和2.56%，差异均有统计学意义(P<0.05)。结论局部晚期宫颈癌患者术前给予2~3个疗程的紫杉醇联合洛铂新辅助化疗有助于降低患者血清中的DcR3和Survivin水平，临床疗效显著。
展开▼
